Erez Chimovits
QuietNamed in filings at Orbimed Genesis
- Board seats filed
- 9
all filings on record
Named in filings at Orbimed Genesis
all filings on record
last 24 months
from a verified or cited source
| FORE US Bio | Biotech & pharma | August 2023 | Orbimed Asia Partners |
| Capstan Therapeutics | Biotech & pharma | November 2021 | Orbimed Asia Partners, Vida Ventures |
| Galecto | Biotech & pharma | September 2020 | Orbimed Asia Partners |
| ImmPACT Bio USA | Biotech & pharma | July 2020 | Orbimed Asia Partners, Venbio Global Strategic |
| ADARx Pharmaceuticals | Biotech & pharma | July 2020 | Bain Capital Life Sciences, Caduceus Capital, Orbimed Asia Partners, TCG Crossover, Tcgx Asia Life Sciences, Vivo Innovation |
| Novus Therapeutics | Biotech & pharma | May 2019 | Orbimed Asia Partners |
| Atox Bio | Biotech & pharma | December 2017 | Orbimed Asia Partners |
| LogicBio Therapeutics | Biotech & pharma | January 2016 | Orbimed Asia Partners |
| Adicet Bio | Biotech & pharma | August 2015 | Caduceus Capital, Orbimed Asia Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Erez Chimovits on the board, based on 9 filed seats with a verified or cited source.